The potential of solanezumab and gantenerumab to prevent Alzheimer’s disease in people with inherited mutations that cause its early onset

Cognitive frailty: a potential target for secondary prevention of dementia

(2017) Francesco Panza et al.   Expert Opinion on Drug Metabolism & Toxicology

Association Between Elevated Brain Amyloid and Subsequent Cognitive Decline Among Cognitively Normal Persons

(2017) Michael C. Donohue et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

2016 Alzheimer's disease facts and figures

(2016)   Alzheimers & Dementia

Perspectives on the Tertiary Prevention Strategy for Alzheimer's Disease

(2016) Xian-Le Bu et al.   Current Alzheimer Research

Emerging drugs to reduce abnormal β-amyloid protein in Alzheimer’s disease patients

(2016) Francesco Panza et al.   EXPERT OPINION ON EMERGING DRUGS

Tau-directed approaches for the treatment of Alzheimer’s disease: focus on leuco-methylthioninium

(2016) Davide Seripa et al.   Expert Review of Neurotherapeutics

An Oral Aβ Vaccine Using a Recombinant Adeno-Associated Virus Vector in Aged Monkeys: Reduction in Plaque Amyloid and Increase in Aβ Oligomers

(2016) Hideo Hara et al.   JOURNAL OF ALZHEIMERS DISEASE

Prevention Trials in Alzheimer’s Disease: Current Status and Future Perspectives

(2016) Jun Wang et al.   JOURNAL OF ALZHEIMERS DISEASE

Tau-directed approaches for the treatment of Alzheimer’s disease: focus on leuco-methylthioninium

(2016) Davide Seripa et al.   Expert Review of Neurotherapeutics

Hypothetical Preclinical Alzheimer Disease Groups and Longitudinal Cognitive Change

(2016) Anja Soldan et al.   JAMA Neurology

Cognitive frailty, a novel target for the prevention of elderly dependency

(2015) Qingwei Ruan et al.   AGEING RESEARCH REVIEWS

A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial

(2015) Tiia Ngandu et al.   LANCET

Prevention of sporadic Alzheimer's disease: lessons learned from clinical trials and future directions

(2015) Sandrine Andrieu et al.   LANCET NEUROLOGY

Three dimensions of the amyloid hypothesis: time, space and 'wingmen'

(2015) Erik S Musiek et al.   NATURE NEUROSCIENCE

CAP—advancing the evaluation of preclinical Alzheimer disease treatments

(2015) Eric M. Reiman et al.   Nature Reviews Neurology

What lessons can be learned from failed Alzheimer’s disease trials?

(2015) Jeremy Toyn   Expert Review of Clinical Pharmacology

A Randomized, Double-Blind, Placebo-Controlled, 16-Week Study of the H3 Receptor Antagonist, GSK239512 as a Monotherapy in Subjects with Mild-to-Moderate Alzheimer’s Disease

(2014) Richard Grove et al.   Current Alzheimer Research

Is there still any hope for amyloid-based immunotherapy for Alzheimerʼs disease?

(2014) Francesco Panza et al.   CURRENT OPINION IN PSYCHIATRY

Amyloid-based immunotherapy for Alzheimer's disease in the time of prevention trials: the way forward

(2014) Francesco Panza et al.   Expert Review of Clinical Immunology

Efficacy and safety studies of gantenerumab in patients with Alzheimer’s disease

(2014) Francesco Panza et al.   Expert Review of Neurotherapeutics

Advances in the prevention of Alzheimer's disease and dementia

(2014) A. Solomon et al.   JOURNAL OF INTERNAL MEDICINE

Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014

(2014) L. S. Schneider et al.   JOURNAL OF INTERNAL MEDICINE

Function, therapeutic potential and cell biology of BACE proteases: current status and future prospects

(2014) Robert Vassar et al.   JOURNAL OF NEUROCHEMISTRY

Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease

(2014) Stephen Salloway et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease

(2014) Rachelle S. Doody et al.   NEW ENGLAND JOURNAL OF MEDICINE

The A4 Study: Stopping AD Before Symptoms Begin?

(2014) R. A. Sperling et al.   Science Translational Medicine

Perspectives on future Alzheimer therapies: amyloid-β protofibrils - a new target for immunotherapy with BAN2401 in Alzheimer’s disease

(2014) Lars Lannfelt et al.   Alzheimers Research & Therapy

The Preclinical Alzheimer Cognitive Composite

(2014) Michael C. Donohue et al.   JAMA Neurology

Long-term associations between cholinesterase inhibitors and memantine use and health outcomes among patients with Alzheimer's disease

(2013) Carolyn W. Zhu et al.   Alzheimers & Dementia

Bapineuzumab and solanezumab for Alzheimer's disease: is the ‘amyloid cascade hypothesis' still alive?

(2013) Haythum O Tayeb et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Cognitive frailty: Rational and definition from an (I.A.N.A./I.A.G.G.) International Consensus Group

(2013) Eirini Kelaiditi et al.   Journal of Nutrition Health & Aging

Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers

(2013) Clifford R Jack et al.   LANCET NEUROLOGY

Immunotherapy for Alzheimer’s disease: hoops and hurdles

(2013) Cynthia A Lemere   Molecular Neurodegeneration

A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease

(2013) Rachelle S. Doody et al.   NEW ENGLAND JOURNAL OF MEDICINE

Preclinical trials in autosomal dominant AD: Implementation of the DIAN-TU trial

(2013) S.M. Mills et al.   REVUE NEUROLOGIQUE

Dominantly Inherited Alzheimer Network: facilitating research and clinical trials

(2013) Krista L Moulder et al.   Alzheimers Research & Therapy

Safety and biomarker effects of solanezumab in patients with Alzheimer’s disease

(2012) Martin Farlow et al.   Alzheimers & Dementia

Safety and Tolerability of the γ-Secretase Inhibitor Avagacestat in a Phase 2 Study of Mild to Moderate Alzheimer Disease

(2012) Vladimir Coric et al.   ARCHIVES OF NEUROLOGY

Alzheimer Mechanisms and Therapeutic Strategies

(2012) Yadong Huang et al.   CELL

Solanezumab for the treatment of mild-to-moderate Alzheimer’s disease

(2012) Bruno P Imbimbo et al.   Expert Review of Clinical Immunology

An Effector-Reduced Anti- -Amyloid (A ) Antibody with Unique A  Binding Properties Promotes Neuroprotection and Glial Engulfment of A 

(2012) O. Adolfsson et al.   JOURNAL OF NEUROSCIENCE

Florbetapir PET analysis of amyloid-β deposition in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional study

(2012) Adam S Fleisher et al.   LANCET NEUROLOGY

Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case-control study

(2012) Eric M Reiman et al.   LANCET NEUROLOGY

A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline

(2012) Thorlakur Jonsson et al.   NATURE

Large Aggregates Are the Major Soluble Aβ Species in AD Brain Fractionated with Density Gradient Ultracentrifugation

(2012) Dag Sehlin et al.   PLoS One

The Serotonin-6 Receptor as a Novel Therapeutic Target

(2012) Hyung-Mun Yun et al.   Experimental Neurobiology

Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

(2011) Clifford R. Jack et al.   Alzheimers & Dementia

Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

(2011) Reisa A. Sperling et al.   Alzheimers & Dementia

The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease

(2011) Marilyn S. Albert et al.   Alzheimers & Dementia

An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease

(2011) Clifford R. Jack et al.   ANNALS OF NEUROLOGY

Mechanism of Amyloid Removal in Patients With Alzheimer Disease Treated With Gantenerumab

(2011) Susanne Ostrowitzki   ARCHIVES OF NEUROLOGY

Anti-β-Amyloid Immunotherapy for Alzheimers Disease: Focus on Bapineuzumab

(2011) Francesco Panza et al.   Current Alzheimer Research

Advances in the identification of γ-secretase inhibitors for the treatment of Alzheimer's disease

(2011) Grazia D'Onofrio et al.   Expert Opinion on Drug Discovery

A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease

(2011) S. Salloway et al.   NEUROLOGY

Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease

(2011) Randall J Bateman et al.   Alzheimers Research & Therapy

Alzheimer’s Prevention Initiative: a proposal to evaluate presymptomatic treatments as quickly as possible

(2010) Eric M Reiman et al.   Biomarkers in Medicine

Safety and Changes in Plasma and Cerebrospinal Fluid Amyloid β After a Single Administration of an Amyloid β Monoclonal Antibody in Subjects With Alzheimer Disease

(2010) Eric R. Siemers et al.   CLINICAL NEUROPHARMACOLOGY

Docosahexaenoic Acid Supplementation and Cognitive Decline in Alzheimer Disease

(2010) Joseph F. Quinn et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

The biochemical aftermath of anti-amyloid immunotherapy

(2010) Chera L Maarouf et al.   Molecular Neurodegeneration

Identification, characterization, and comparison of amino-terminally truncated Aβ 42 peptides in Alzheimer's disease brain tissue and in plasma from Alzheimer's patients receiving solanezumab immunotherapy treatment

(2009) Ronald B. DeMattos et al.   Alzheimers & Dementia

Selection of an anti-Abeta antibody that binds various forms of Abeta and blocks toxicity both in vitro and in vivo

(2009) Ryan J. Watts et al.   Alzheimers & Dementia

Atomoxetine Augmentation of Cholinesterase Inhibitor Therapy in Patients With Alzheimer Disease: 6-Month, Randomized, Double-Blind, Placebo-Controlled, Parallel-Trial Study

(2009) Richard C. Mohs et al.   AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY

A  Immunotherapy: Intracerebral Sequestration of A  by an Anti-A  Monoclonal Antibody 266 with High Affinity to Soluble A 

(2009) K. Yamada et al.   JOURNAL OF NEUROSCIENCE

S1-02-02: Natural human antibodies targeting amyloid aggregates in intravenous immunoglobulin

(2008) Norman R. Relkin   Alzheimers & Dementia

Alzheimer Disease Pathology As a Host Response

(2008) Rudy J. Castellani et al.   JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY

Safety, efficacy, and biomarker findings of PBT2 in targeting Aβ as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial

(2008) Lars Lannfelt et al.   LANCET NEUROLOGY

Thirty years of Alzheimer's disease genetics: the implications of systematic meta-analyses

(2008) Lars Bertram et al.   NATURE REVIEWS NEUROSCIENCE